Generic Zocor to challenge Lipitor
NEW YORK — June 23 will be awful for Merck & Co., but the question looming is just how bad it will be for Pfizer Inc.
Merck will lose patent protection on cholesterol-lowering agent Zocor, which racked $4.4 billion in revenue last year. Zocor's fate is inevitable: Its sales will shrivel as cheap generic alternatives flood the market. What's unclear is the destiny of Pfizer's Lipitor, the world's best-selling drug, which controls nearly 55 percent of the $16 billion U.S. cholesterol market
· Read The Full Lipitor Article From Jackson Clarion Ledger -->
·
Read All Lipitor (Atorvastatin) News Stories -->